Clinical Trial Update: A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating intravenous Eritoran (E5564) administered around bone marrow engraftment in leukemia patients undergoing matched related donor bone m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• Eritoran (E5564)

Snippet

Sponsor: Eisai Inc. | Conditions: Leukemia | Phase 1 | Status: TERMINATED